Rohto Pharmaceutical Co.,Ltd.
4527
株式のランク
#3855
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global... Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
株価
$19.03
時価総額
$4.30B
変化（1日）
0.15%
変化（1年）
16.15%
国
JP
取引 Rohto Pharmaceutical Co.,Ltd. (4527)
カテゴリー
Consumer Defensive
Rohto Pharmaceutical Co.,Ltd.（4527）の利益
Jun 2026 時点の利益 TTM: $303.71M
Rohto Pharmaceutical Co.,Ltd. の最新の財務報告によると、同社の現在の利益は $303.71M です。2024 年には $274.31M の利益を上げ、これは 2023 年の利益 $258.26M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Rohto Pharmaceutical Co.,Ltd. の利益の推移（2008 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $303.71M | 7.55% |
| 2025 | $282.40M | 2.95% |
| 2024 | $274.31M | 6.21% |
| 2023 | $258.26M | 12.49% |
| 2022 | $229.58M | 10.53% |
| 2021 | $207.71M | 2.77% |
| 2020 | $202.12M | 37.64% |
| 2019 | $146.85M | -7.24% |
| 2018 | $158.31M | 19.53% |
| 2017 | $132.44M | 4.19% |
| 2016 | $127.12M | 10.88% |
| 2015 | $114.65M | -19.00% |
| 2014 | $141.54M | -2.14% |
| 2013 | $144.64M | -14.82% |
| 2012 | $169.81M | 4.81% |
| 2011 | $162.02M | 21.98% |
| 2010 | $132.83M | 41.40% |
| 2009 | $93.94M | -24.26% |
| 2008 | $124.03M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $20.38B | 6,609.37% |
US
|
|
| $9.83B | 3,135.44% |
FR
|
|
| $2.94B | 868.36% |
US
|
|
| $1.55B | 410.35% |
IN
|
|
| $517.00M | 70.23% |
US
|
